Oncology

Gastric (stomach) cancer

Hospitals in China recommended for Gastric (stomach) cancer, with Fudan specialty rankings and sources. Related specialties: Oncology, General Surgery, Gastroenterology.

Ask about this condition

General information only. It is not a diagnosis or a substitute for professional advice.

Last updated: 2026-11-03

Related specialties: Oncology · General Surgery · Gastroenterology
Also known as: stomach cancer, gastroesophageal junction cancer, Claudin18.2

Recommended hospitals

Hospitals are listed in order of recommendation, based on the Fudan specialty reputation ranking and published sources. This is not medical advice.

1
Cancer Hospital, Chinese Academy of Medical Sciences
BeijingGrade 3A Public HospitalOncology #1International patient department
National Cancer Center, #1 in Fudan ranking, leading multidisciplinary treatment for gastric cancer with rich experience in high-incidence tumors like esophagogastric junction cancer; Ranked #1 in the 2023 Fudan Oncology specialty reputation ranking
Sources: rank.cn-healthcare.com cicams.ac.cn
2
Peking University Cancer Hospital
BeijingGrade 3A Public HospitalOncology #4
High in Fudan oncology ranking, leading individualized precision treatment and MDT for gastric cancer, distinctive GI tumor specialty with high case volume; Ranked #4 in the 2023 Fudan Oncology specialty reputation ranking
Sources: rank.cn-healthcare.com sohu.com
3
Sun Yat-sen University Cancer Center
GuangzhouGrade 3A Public HospitalOncology #2International patient department
#2 in Fudan oncology ranking, strong comprehensive treatment for GI tumors including gastric cancer, many clinical trials and leading case volume in South China; Ranked #2 in the 2023 Fudan Oncology specialty reputation ranking
Sources: rank.cn-healthcare.com sohu.com
4
Fudan University Shanghai Cancer Center
ShanghaiGrade 3A Public HospitalOncology #3International patient department
Top 3 in Fudan oncology ranking, colorectal cancer center supports gastric cancer treatment with high surgical volume, precision medicine platform and high survival rates; Ranked #3 in the 2023 Fudan Oncology specialty reputation ranking
Sources: rank.cn-healthcare.com sohu.com
5
Peking Union Medical College Hospital
BeijingGrade 3A Public HospitalGeneral Surgery #1International patient department
Ranked #1 in the 2023 Fudan General Surgery specialty reputation ranking
Sources: rank.cn-healthcare.com
6
Tianjin Medical University Cancer Institute and Hospital
TianjinGrade 3A Public HospitalOncology #5International patient department
#5 in Fudan oncology ranking, good standardized diagnosis/treatment and research foundation for gastric cancer as a national clinical research center; Ranked #5 in the 2023 Fudan Oncology specialty reputation ranking
Sources: rank.cn-healthcare.com sohu.com

Other notable hospitals

Shandong Cancer Hospital and Institute2023 Fudan Oncology specialty rank #6rank.cn-healthcare.com
Zhejiang Cancer Hospital (Cancer Hospital of the University of Chinese Academy of Sciences)2023 Fudan Oncology specialty rank #7rank.cn-healthcare.com
Jiangsu Cancer Hospital2023 Fudan Oncology specialty rank #9rank.cn-healthcare.com
Sichuan Cancer Hospital2023 Fudan Oncology specialty rank #10rank.cn-healthcare.com

Related news

View all

Oncology2026-10-16

Renji Hospital First to Complete Three Post-Approval Solid Tumor CAR-T Full-Course Treatments and Efficacy Assessments

The oncology team completed post-market CT041 (world's first solid tumor CAR-T) treatment in three advanced gastric cancer patients. Patients improved symptomatically, including resumption of oral intake after tube removal, with stable disease, making it the global center with the most such cases.

Renji Hospital Shanghai Jiao Tong University School of Medicine

HKU-Shenzhen Hospital Successfully Applies World's First Approved Solid Tumor CAR-T Therapy

Video

OncologyInternational patient story2026-06-26

HKU-Shenzhen Hospital Successfully Applies World's First Approved Solid Tumor CAR-T Therapy

HKU-Shenzhen Hospital applied the world's first approved solid tumor CAR-T therapy to an American patient with advanced gastroesophageal junction adenocarcinoma, resulting in significantly reduced tumor markers and near complete remission. Approved by China's NMPA, it provides a breakthrough option for solid tumor patients.

The University of Hong Kong-Shenzhen Hospital

Oncology2026-06-23

Hospital Completes First Fully Robot-Assisted Laparoscopic Proximal Gastrectomy with Kamikawa Anastomosis

The gastrointestinal surgery team at the General Surgery Center performed this advanced function-preserving radical surgery on an elderly patient with gastroesophageal junction adenocarcinoma, reducing risks of complications such as reflux and reaching internationally leading standards.

Beijing Friendship Hospital, Capital Medical University

Oncology2026-06-01

The Lancet Publishes Landmark Phase III Results of Serplulimab for Perioperative Gastric Cancer Treatment

The ASTRUM-006 study led by Ji Jiafu and Shen Lin demonstrated that serplulimab plus chemotherapy for neoadjuvant/adjuvant therapy significantly improved event-free survival and pathological complete response rate in PD-L1-positive locally advanced gastric cancer, a major breakthrough in perioperative treatment.

Peking University Cancer Hospital

A Lifeline Across the Ocean: An American Patient with Advanced Cancer Travels from Los Angeles to Shenzhen for Treatment

Video

OncologyInternational patient story2026-10-27

A Lifeline Across the Ocean: An American Patient with Advanced Cancer Travels from Los Angeles to Shenzhen for Treatment

Larry Black of Los Angeles (with his wife Jamie) had advanced gastroesophageal-junction adenocarcinoma with peritoneal metastasis that progressed through multiple lines of therapy; 99% of tumor cells were Claudin18.2 2+/3+. After China's NMPA approved the world's first solid-tumor CAR-T (satri-cel, Claudin18.2-targeted) in June 2026, the couple travelled to the International Medical Center of HKU-Shenzhen Hospital. Prof. Pan Hongming's team infused the CAR-T cells on 29 Sep 2026; after cytokine release syndrome was managed with tocilizumab, CA19-9 fell from 8,200 to 57.6 U/mL with marked tumor shrinkage and near-complete remission, and he was discharged.

The University of Hong Kong-Shenzhen Hospital (International Medical Center)

OncologyInternational patient story2026-10-13

Across 10,000 km for a Chance at Life: Hangzhou Completes Its First Solid-Tumor CAR-T Treatment for an Overseas Chinese-American Gastric Cancer Patient

The team of Zheng Yu at Sir Run Run Shaw Hospital used the world's first approved solid-tumor CAR-T (satri-cel, CLDN18.2-targeted) to treat a Chinese-American advanced gastric cancer patient whose multi-line treatment in the US had failed — Zhejiang's first such case.

Sir Run Run Shaw Hospital